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Abstract
Background: Rheumatoid Arthritis is a chronic disease leading to decreased quality of life with a rather variable
response rate to Disease Modifying Anti Rheumatic Drugs. Methotrexate (MTX) is the gold standard therapy in
Rheumatoid Arthritis. The Multidrug resistance Related Protein and Multi Drug Resistance protein 1, also called
P-glycoprotein-170 transporters can alter the intracellular concentration of different drugs. Methotrexate is an
MRP1 substrate and thus the functional activity of MRP1 might have a clinical impact on the efficiency of the
Methotrexate-therapy in Rheumatoid Arthritis.
Methods: We have compared the functional Multidrug Activity Factors (MAF) of the MDR1 and MRP1 transporters
of Peripheral Blood Leukocytes of 59 Rheumatoid Arthritis patients with various response rate to MTX-therapy
(MTX-responder, MTX-resistant and MTX-intolerant RA-groups) and 47 non-RA controls in six different leukocyte
subpopulations (neutrophil leukocytes, monocytes, lymphocytes, CD4+, CD8+ and CD19+ cells). There was a
decreased MAF of RA patients compared to non- Rheumatoid Arthritis patients and healthy controls in the
leukocyte subpopulations. There was a significant difference between the MAF values of the MTX-responder and
MTX intolerant groups. But we have not found significant differences between the MAF values of the MTX-
responder and MTX-resistant Rheumatoid Arthritis -groups.
Results: Our results suggest that MDR1 and MRP1 functional activity does not seem to affect the response rate to
MTX-therapy of Rheumatoid Arthritis-patients, but it might be useful in predicting MTX-side effects. We have
demonstrated the decreased functional MDR-activity on almost 60 Rheumatoid Arthritis patients, which can be
interpreted as a sign of the immune-suppressive effect of the MTX-treatment.
Keywords: ABC-transporter, Disease modifying anti rheumatic drugs-DMARDs, Methotrexate, MultiDrug resistance,
Rheumatoid arthritis
Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease of small articulations often leading to functional im-
pairments and seriously affecting the quality of life [1].
Currently methotrexate (MTX) is the gold standard
therapy of the disease modifying antirheumatic drugs
(DMARDs), however the response rate is rather variable
and many patients are completely resistant to MTX
therapy [2, 3]. It has been previously reported, that the
Multidrug Resistance Protein 1 (MDR1) and the Multi-
drug resistance Related Protein 1 (MRP1) transporters -
responsible for chemo-resistance of tumor cells - may
also have pathophysiological role in different chronic
diseases, including rheumatoid arthritis [4, 5].
ATP Binding Cassette (ABC) -transporters are ATP-
driven efflux pumps of the cell membranes present on
many cell surfaces, but especially on barriers, bile-
transporters, kidney-tubules, enterocytes, blood–brain
barriers and inflammatory cells. These transporters ex-
trude xenobiotic substances including various drugs via
active transport [6]. According to their wide substrate
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specificity, these transporters may interfere with the ab-
sorption and distribution of many therapeutic agents
and could influence their serum concentration which in
turn can alter the efficiency of different treatments.
The MRP1-transporter substrate MTX is the most
widely used DMARD. Therefore, the elevated MDR1/
MRP1 expression in the synovium of RA-patients sug-
gested prognostic role to these proteins [3, 7–10]. On
the other hand, many studies have reported, that expres-
sion levels of MDR1 and MRP1 proteins do not correlate
with the functional activity of these proteins predicting
the superiority of functional determination of transport
activities over expression data [11–13].
The clinical relevance and usefulness of calcein-AM
based functional multidrug-assay has been demonstrated
in acute myeloid leukemia [14]. We have optimized this
assay for the determination of functional MDR1- and
MRP1-activity of different peripheral blood leukocyte
subtypes of RA-patients to study their possible role in
the response to DMARD-therapy.
Results
Our results suggest that MDR1 and MRP1 functional activ-
ity does not seem to affect the response rate to MTX-
therapy of Rheumatoid Arthritis-patients, but it might be
useful in predicting MTX-side effects. We have demon-
strated the decreased functional MDR-activity on almost 60
Rheumatoid Arthritis patients, which can be interpreted as
a sign of the immune-suppressive effect of the MTX-
treatment. First, we have compared the MAFTotal,
MAFMDR1 and MAFMRP1 of all six leukocyte subgroups of
the five different patient groups to define if there is any sig-
nificant difference between any of those. We did not find
significant differences in the MAF-values of the RA-
patients according to their responder-rate to MTX-therapy.
Because most of the patients were taking other drugs as
well, we have collected the data of medicine-intake with
doses and analyzed the potential effect of these on each
MAF value. After adjusting the model with the significant
drug-effects on the MAF-values, we have compared each
RA and non-RA groups pairwise with each other (Table 1).
With the adjusted model, the MAFMDR1 of the granulo-
cytes was significantly higher in the MTX-responder group
than the MTX-resistant group. Another finding was that
the MTX-intolerant RA-group had significantly higher
MAFMRP1 than the MTX-responders in the granulocyte
subpopulation (Fig. 1). Unfortunately, the granulocyte rep-
resentation was sometimes low in our samples and not all
blood samples contained enough granulocytes to be subject
of precise MAF determination.
With a potential clinical application, another interest-
ing finding was the difference in MAF values in the
granulocyte, monocyte and CD19+ cells between the
MTX-responder and the MTX-intolerant groups. The
MAFMRP1 of granulocytes in the MTX-intolerant group
was significantly higher than that of MTX-responder
RA-patients, and the MAFMDR1 of MTX-intolerant
group was significantly higher than that of MTX-
responder RA-patients in the granulocyte population. In
contrast, we have found significantly lower MAFMDR1 of
the CD19+ cells of RA-patients intolerant to MTX-
therapy than those of MTX-responders.
According to our results, the most prominent difference
was found between the different RA-groups and the two
control groups in almost all leukocyte subgroups. Granu-
locytes and CD19+ cells had higher MAFMRP1 in the RA-
groups with the adjusted model, while the other leukocyte
groups have higher MAFTotal and MAFMDR1 and lower
MAFMRP1. The differences become more pronounced in
the following sequence: monocyte, lymphocyte, CD4+
cells and CD8+ cells (Fig. 1).
Discussion
The first report on the potential role of MDR-proteins
in RA found significantly higher MDR1 (P-glycoprotein)
expression in steroid-treated RA-patients independently
from other factors [15]. Later, in a small study by Yudoh
et al. increased expression of P-Glycoprotein on Th1-
cells correlated with drug resistance was observed after
two month of therapy with bucillamin or sulfsalazine
[16]. As DMARD therapy moved forwards, the MRP1-
susbtrate MTX and the role of the MRP1 proteins have
emerged in defining the response to MTX-therapy [17].
Despite our original hypothesis on the effect of func-
tional MDR-activity on the response rate to MTX-therapy,
in this study we were not able to demonstrate significant
differences in the functional MDR-activities of MTX-
responder and MTX-resistant RA patients, except for the
higher MAFMDR1 of granulocytes of MTX-responders
than MTX-resistants. However, we found another signifi-
cant difference in the MAF values of the granulocytes: the
MTX-intolerant RA-group had significantly higher
MAFMRP1 than the MTX-responder RA-group. This dif-
ference may be useful in identifying the MTX-intolerant
patients, who cannot benefit from MTX-therapy.
The MAFMRP1 of granulocytes and the MAFMDR1 of
monocytes was significantly higher in the MTX-intolerant
patients than in MTX-responders, while they had signifi-
cantly lower MAFMDR1 in the CD19+ population. The
combination of these three results could be clinically rele-
vant in determining the MTX intolerant patient population.
In clinical setting: if a patient needs dose escalation of
MTX and has side effects probably related to MTX, a
scheduled MDR-functional assessment finding the upper
mentioned triad of granulocytic MAFMRP1 and mono-
cytic, CD19+ lymphocytic MAFMDR1 values might help
in deciding to turn off ineffective dose-escalation of
MTX. Titrating MTX-dosage in RA-patients is quite
Micsik et al. Diagnostic Pathology  (2015) 10:216 Page 2 of 8
Table 1 Shows the significant differences between different patient groups with (adjusted p) and without (p) the adjustment of
the medicine effects on the different MAF values
Cell type MAF type Group 1 Mean Group 2 Mean p Adjusted p After adjustment
Granulocytes Total MTX-intolerant 15 nonRA control 11 0,0068 0,0026 significant
Granulocytes Total MTX-responder 14 nonRA control 11 0,0097 0,2005 non significant
Granulocytes MRP1 MTX-intolerant 5 MTX-responder 2,5 0,3664 0,0276 significant
Granulocytes MRP1 MTX-intolerant 5 nonRA control −2,5 0,0897 0,0472 significant
Granulocytes MDR1 MTX-resistant 11 MTX-responder 10 0,2475 0,0284 significant
Monocytes Total MTX-responder 7 nonRA control 12 0,0214 0,1114 non significant
Monocytes Total MTX-responder 7 Healthy control 15,98 0,0023 0,6893 non significant
Monocytes Total MTX-intolerant 9 Healthy control 15,98 0,0266 0,9483 non significant
Monocytes Total MTX-resistant 7,5 Healthy control 15,98 0,0075 0,7462 non significant
Monocytes MDR1 MTX-resistant 7 Healthy control 11,99 0,0044 0,6792 non significant
Monocytes MDR1 MTX-resistant 7 nonRA control 12,5 0,0245 0,4869 non significant
Monocytes MDR1 MTX-intolerant 7 Healthy control 11,99 0,0071 0,3590 non significant
Monocytes MDR1 MTX-responder 5,5 MTX-intolerant 7 0,8766 0,0276 significant
Monocytes MDR1 MTX-intolerant 7 nonRA control 12,5 0,0443 0,0472 significant
Lymphocytes Total Healthy control 34,29 MTX-resistant 27,5 0,0023 0,0504 trend
Lymphocytes Total Healthy control 34,29 MTX-intolerant 26 0,0014 0,0121 significant
Lymphocytes Total Healthy control 34,29 nonRA control 29 0,0359 0,0537 trend
Lymphocytes Total Healthy control 34,29 MTX-responder 26 0,0011 0,0084 significant
Lymphocytes MRP1 nonRA control 0 MTX-responder 6,5 0,0842 0,0510 trend
Lymphocytes MRP1 nonRA control 0 MTX-intolerant 7 0,0532 0,0139 significant
Lymphocytes MRP1 nonRA control 0 MTX-resistant 4 0.0689 0,0022 significant
Lymphocytes MRP1 nonRA control 0 Healthy control 10,55 0,0023 0,0014 significant
Lymphocytes MDR1 nonRA control 32 Healthy control 21,73 0,0129 0,0847 trend
Lymphocytes MDR1 nonRA control 32 MTX-responder 22,5 0,0164 0,0084 significant
Lymphocytes MDR1 nonRA control 32 MTX-resistant 21,5 0,003 0,0008 significant
Lymphocytes MDR1 nonRA control 32 MTX-intolerant 21 0,002 0,0007 significant
CD4+ cells Total nonRA control 23,5 MTX-resistant 20 0,0156 0,0270 significant
CD4+ cells Total Healthy control 26,81 MTX-responder 21,5 0,036 0,2212 non significant
CD4+ cells Total nonRA control 23,5 MTX-intolerant 21 0,0211 0,0064 significant
CD4+ cells Total Healthy control 26,81 MTX-resistant 20 0,0174 0,0278 significant
CD4+ cells Total Healthy control 26,81 MTX-intolerant 21 0,0032 0,0081 significant
CD4+ cells MRP1 nonRA control −1 Healthy control 7,8 0,0118 0,0103 significant
CD4+ cells MRP1 Healthy control 7,8 MTX-resistant 2 0,076 0,0492 significant
CD4+ cells MRP1 nonRA control −1 MTX-intolerant 4 0,0121 0,0950 trend
CD4+ cells MDR1 nonRA control 27,5 MTX-intolerant 16 0,0004 0,0015 significant
CD4+ cells MDR1 nonRA control 27,5 MTX-resistant 17,5 0,0046 0,0154 significant
CD4+ cells MDR1 nonRA control 27,5 MTX-responder 17 0,0364 0,0698 trend
CD4+ cells MDR1 nonRA control 27,5 Healthy control 17,7 0,0108 0,0448 significant
CD8+ cells Total nonRA control 35 MTX-intolerant 31 0,0262 0,0585 trend
CD8+ cells Total nonRA control 35 MTX-resistant 31 0,0078 0,0046 significant
CD8+ cells Total nonRA control 35 MTX-responder 29 0,0008 0,0001 significant
CD8+ cells Total Healthy control 40,15 MTX-intolerant 31 0,0036 0,0120 significant
CD8+ cells Total Healthy control 40,15 MTX-resistant 31 0,0004 0,0032 significant
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laborious, so disclosing patients who will not benefit from
dose elevation and thus avoiding the harmful side effects
of MTX-treatment might have clinical relevance in the fu-
ture. Although, further studies are still needed for the clin-
ical implementation/validation of these findings.
There are only few previous studies on RA patients in-
vestigating the role of MDR-transporters in MTX-
response. Wolf et al. determined the functional activity
of Reduced Folate Carrier (RFC), which transports MTX
into the cells, and MRP1, which effluxes MTX out of the
Table 1 Shows the significant differences between different patient groups with (adjusted p) and without (p) the adjustment of
the medicine effects on the different MAF values (Continued)
CD8+ cells Total Healthy control 40,15 MTX-responder 29 0,0002 0,0003 significant
CD8+ cells Total MTX-responder 29 MTX-intolerant 31 0,1309 0,0601 trend
CD8+ cells MRP1 Healthy control 14,35 MTX-intolerant 5 0,0003 0,0004 significant
CD8+ cells MRP1 Healthy control 14,35 MTX-resistant 6 0,002 0,0017 significant
CD8+ cells MRP1 Healthy control 14,35 MTX-responder 6,5 0,0069 0,0031 significant
CD8+ cells MRP1 Healthy control 14,35 nonRA control 0 0,0053 0,0131 significant
CD8+ cells MDR1 nonRA control 37,5 MTX-intolerant 28 0,0302 0,0634 trend
CD8+ cells MDR1 nonRA control 37,5 MTX-resistant 24,5 0,0071 0,0014 significant
CD8+ cells MDR1 nonRA control 37,5 MTX-responder 21,5 0,0057 0,0012 significant
CD8+ cells MDR1 nonRA control 37,5 Healthy control 21,93 0,0089 0,0324 significant
CD19+ cells Total nonRA control 20,5 MTX-resistant 16,5 0,0435 0,6173 non significant
CD19+ cells MRP1 nonRA control 0 MTX-intolerant 5 0,0426 0,0057 significant
CD19+ cells MRP1 nonRA control 0 MTX-resistant 3,5 0,3154 0,0180 significant
CD19+ cells MDR1 nonRA control 22,5 MTX-intolerant 14 0,0175 0,0491 significant
CD19+ cells MDR1 nonRA control 22,5 MTX-resistant 15 0,0109 0,0000 significant
CD19+ cells MDR1 MTX-responder 17 MTX-intolerant 14 0,4548 0,0058 significant
Significant p-values are highlighted in bold
Fig. 1 Significant differences among various patient-groups. The differences among the 5 groups are shown with arrows pointing towards the
significantly higher MAF values according to the adjusted/justified model. Only significant differences with p < 0,05 are shown
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cells. They logically anticipated that RFC+ and MRP-
patients should have better response to MTX-therapy,
but instead, they observed the opposite result, since
these patients had the worse response rate, while the
lack or presence of both proteins was linked to signifi-
cantly better therapeutic outcome [18]. In another study,
they determined the mRNA-levels of FolylPolyGlutamyl
Synthetase (FPGS) enzyme, which accumulates MTX
into the cells, and they also found the contradictory re-
sult, such that FPGS mRNA expression is an independ-
ent predictive factor associated with poor response to
MTX-therapy in RA patients [19]. Considering the ra-
ther complex metabolic and effector mechanism of
MTX, more studies are needed to evaluate the effects of
the various functional activities on MTX-response [20].
Our most relevant finding was the major difference be-
tween the RA and control groups. In general, the signifi-
cant differences were the decreased MAFTotal and
MAFMDR1 and higher MAFMRP1 in the RA patients com-
pared to the control-patients calculated with or without
adjustment of the effects of medicine-intake. This differ-
ence was most prominent in case of the CD8+ cells. These
cells had the highest MAF-values, which is in agreement
with the literature [21, 22]. Interestingly, although MTX is
an MRP1 substrate, the most important and significant
differences were found in MAFTotal and MAFMDR1. Hider
et al. described the down regulation of MRP1 protein in
PBLs by immunocytochemistry of early RA-patients after
six months of MTX-therapy. They studied the MRP1 ex-
pression of 18 RA patients and 14 control persons, but
they also couldn’t find any difference between the MRP1
levels of the responder and non-responder RA-patients
[23]. In our study we found similar results, but we used
the dynamic data of functional activity determination of
MDR1 and MRP1-proteins instead of the static represen-
tation of MRP1 proteins. This, according to the earlier
data, may give better insight to the significance of the
MDR-proteins on treatment. Furthermore, comparing 3
RA-groups of altogether 59 RA-patients and two control
groups of altogether 47 persons, we found multiple signifi-
cant differences between those groups. Our results dem-
onstrate that MTX-treatment inhibits total MDR and
MDR1 functional activity in RA-patients.
Conclusions
In conclusion, by comparing the MAF values of six
leukocyte subpopulations among 3 RA-patient and 2
control groups, we have found significant difference in
case of granulocytes between the MTX-responder and
MTX-resistant RA-group. Our results have shown mul-
tiple differences in MAF values of the MTX-responder
and MTX-intolerant RA-groups, and therefore, determin-
ing MAF in RA-patients might be useful in predicting
MTX-intolerance. Titrating MTX-dosage in RA-patients
is quite laborious, so disclosing patients who will not
benefit from dose elevation and thus avoiding the harmful
side effects of MTX-treatment may have clinical relevance
in the future. Our most relevant finding was, however, the
decreased functional MDR1- and MRP1-activity in MTX




RA patients were categorized by their DAS28 improvement
rate into MTX-responder (n = 18) and MTX-resistant
(n = 20) groups. An additional MTX-intolerant group was
also selected as RA-patients who terminated MTX-therapy
(n = 21) due to intolerable side effects. The two control
groups were composed as either hospitalized (due to other
diseases or traumas) patients without RA (n = 20) as well
as healthy, young volunteers (n = 27). Altogether, 106 sam-
ples were grouped in three RA-groups (n = 59) and two
control groups (n = 47). All peripheral blood samples were
collected with the approval of the national and local ethical
committee (ETT TUKEB: Scientific and Research Ethics
Committee of the Medical Research Council. Ministry of
Health, Medical Research Council,Budapest, H-1051, Arany
János u. 6–8, Hungary.) and all patients were involved after
signing their written agreement. Blood samples were taken
in 5 ml BD Vacutainer tubes with EDTA (BD #367861)
and stored at 4 °C until transported and processed within 6
h after sampling. PBLs were isolated using HISTOPAQUE
1077 (Sigma-Aldrich, 10771).
Calcein assay
The original calcein assay was obtained from the Multi-
DrugQuant Assay™ (Product No. 5 599880 083012,
SOLVO Biotechnology Inc. Budaörs, Hungary, http://
www.solvobiotech.com/). MDQuant Assay™ was used to
determine the functional activity of MDR1 and MRP1
transporters in MAF (Multidrug Activity Factor), which
is a dimensionless and standardized value calculated by
the mathematical formula: MAFTotal = 100 x (FVerapamil -
FHBSS)/ FVerapamil; MAFMRP1 = 100 x (FMK571 - FHBSS)/
FVerapamil; MAFMDR1 = MAFTotal – MAFMRP1 where F
stands for the average mean calcein-fluorescence
values of the parallel samples. Functional MDR Activ-
ity Factor (MAF) was determined in six PBL popula-
tions (granulocytes, monocytes, lymphocytes, CD4+,
CD8+, CD19+ cells).
Immunocytochemistry
Immunostaining of the different PBL-subpopulations
was performed at room temperature by incubating the
blood cells in 100 μl HBSS containing either 1 μg of
mouse anti-IgG1 antibody for isotype control (X0931,
Dako) or 6ul anti-CD3,4,8 (CD3: C7225, CD4: C24865,
Micsik et al. Diagnostic Pathology  (2015) 10:216 Page 5 of 8
CD8: C9494, Dako) or 12ul of anti-CD19 (C24825,
Dako). The immunolabeling was visualized by incuba-
tion with 1 μg secondary Cy5-conjugated goat anti-
mouse IgG antibody (115-175-003, Jackson Immuno
Research).
Viability staining
Non-viable cells were labeled by incubation in 200 μL
HBSS containing 1 μg/ml propidium iodide (PI; 287075,
Sigma-Aldrich,) for 30 min at room temperature.
Determination of MAF-values of different white blood cell
subpopulations
Measurements were performed on a FacsCalibur (Becton
Dickinson, Franklin Lakes, NJ, USA) flow cytometer.
The viable cells were selected by the positive staining
with Calcein and lack of PI staining. Granulocytes,
monocytes and lymphocytes were gated on the FSC-SSC
scatterplot. The CD4, CD8 and CD19 positive subpopu-
lations were gated based on their positivity with the cor-
responding antibody detected at FL4 against the non-
specific binding detected with IgG1 isotype control.
(Gating algorithm is shown in Fig. 2.) The shifts in
the calcein signal of the leukocyte subpopulations
were determined with different MDR-blockers (verap-
amil and MK-571) compared to HBSS control.
MAFTotal, MAFMDR1 and MAFMRP1 was calculated on
each subpopulations (Fig. 3).
Statistical methods
MAF measurements were modeled using analysis of co-
variance (ANCOVA) with residual error stratified in pa-
tient groups to allow for unequal variances. Models were
fitted using the R statistical system (R Development
Core Team 2007, ISBN 3-900051-07-0), with the GLS
(generalized least squares) procedure of the NLME pack-
age (R Core team, 2007, R-package version 3.1-86).
Models were compared by using maximum likelihood
(ML) fits, and Wald-type significance tests were
performed using restricted maximum likelihood (REML)
estimates. Differences were considered statistically sig-
nificant below the level of p = 0.05. The following pre-
dictors were considered during model selection: patient
group (5 levels), sample storage duration (continuous),
drug doses of methotrexate, delagil, arava, medrol
(continuous), administration of the same drugs (yes/
no), administration of NSAIDs (yes/no). We have se-
lected the best model using the Akaike Information
Criterion (AIC) (Akaike 1974: A new look at the stat-
istical model identification. IEEE Transactions on
Automatic Control 19 (6): 716–723.) All subsets re-
gression was not computationally feasible due to the
large number of predictors, so forward and backward
Fig. 2 Gating out CD3+ cell population. Part a shows how the lymphocytes are gated with R1 in the FSC-SideSCatter dot-plot. The cells in R1 gate are
shown on the Fl1-Fl3 graph of part b, where the viable cells are gated out by the R2 gate. Part c and d shows how the viable lymphocytes of R2 gate
stain with anti-CD3 stain. R3 gate on the FL4-SSC graph is positioned to select out only the CD3+ cells
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stepwise variable selection algorithms were applied.
When the stepwise algorithm yielded a model where
the same drug was included both as a continuous and
binary predictor, we checked if the coefficients corre-
sponded to a monotonous dose-effect relationship. In
case of non-monotonicity we have considered the two
parameters for the same drug as overfitting, dropped
the model and the stepwise algorithm was restarted
twice, first omitting the binary dose variant, second
omitting the continuous one. When the stepwise algo-
rithms led to different models, the one with lowest
AIC value was selected.
Fig. 3 Calculating the MAF-values. This figure shows the shifts in the Fl1-Calcein-signal with the different MDR-blockers. Part a shows the two
parallel samples treated with the MDR1 and MRP1 blocker Verapamil (Fl1-Calcein mean 645.72 and 619.07). Part b shows the two parallel samples
of the controls incubated in HBSS (Fl1 mean 406.42 and 428.39). Part c shows the two parallel samples treated with the MRP1 blocker MK-571
(Fl1-Calcein 436.39 and 389.89). With these Fl1-Calcein values the different MAFs of the CD3+ lymphocytes are as follows MAFTotal = 34,
MAFMRP1 = 0, MAFMDR1 = 34
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